Regenerex Pharma (RGPX) Research & Development (2018 - 2025)
Regenerex Pharma (RGPX) reported Research & Development of $136432.0 for Q3 2025, down 78.85% on a QoQ basis from $645099.0 in Q1 2025.
Regenerex Pharma (RGPX) has 4 years of Research & Development data on file, last reported at $136432.0 in Q3 2025.
- Quarterly Research & Development changed N/A year-over-year to $136432.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $798911.0 (changed N/A YoY) and the FY2025 annual result came in at $662479.0, down 72.4% from the prior year.
- Research & Development eased to $136432.0 in Q3 2025 per RGPX's latest filing, from $645099.0 in the prior quarter.
- Across five years, Research & Development topped out at $2.4 million in Q3 2023 and bottomed at $17380.0 in Q4 2024.
- The 3-year median for Research & Development is $390765.5 (2025), against an average of $799727.8.
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 136,432.00 |
| Mar 31, 2025 | 645,099.00 |
| Dec 31, 2024 | 17,380.00 |
| Sep 30, 2023 | 2.40 Mn |
| Dec 31, 2018 | 300.00 |